Intersect ENT—a medical technology company located in Menlo Park, California—needed a partner to consult them on naming strategies and lead them through their first regulatory submission. Brandsymbol was engaged to develop a proprietary brand name for a less invasive, steroid-releasing sinus implant for patients with recurring ethmoid sinus obstructions. After trying three unique naming strategies during global creative development, we delivered the proprietary brand name SINUVA™. Brandsymbol developed the submission reports and coordinated with the FDA throughout the submission process on the introduction of the POCA 4.0 system, leading to the approval of SINUVA in May 2017. Our team also developed a recognizable logo and packaging design for the product.